- Home
- TLS vs AVIR Comparison
TLS vs AVIR Comparison
Compare TLS & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLS | AVIR |
|---|---|---|
| Founded | 1969 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.1M | 271.9M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TLS | AVIR |
|---|---|---|
| Price | $5.29 | $3.41 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $7.75 | $6.00 |
| AVG Volume (30 Days) | ★ 1.0M | 383.5K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $144,400,000.00 | N/A |
| Revenue This Year | $52.27 | N/A |
| Revenue Next Year | $20.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.44 | N/A |
| 52 Week Low | $1.83 | $2.46 |
| 52 Week High | $8.36 | $4.02 |
Technical Indicators
Market Signals| Indicator | TLS | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 55.54 |
| Support Level | $4.95 | $3.29 |
| Resistance Level | $5.19 | $3.63 |
| Average True Range (ATR) | 0.24 | 0.13 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 37.57 | 52.03 |
Price Performance
Historical ComparisonAbout TLS Telos Corporation
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).